Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

Embodiments of the invention provide methods of synthesizing .sup.18F-tetrafluoroborate (.sup.18F-TFB) via direct radiofluorination on boron trifluoride (BF.sub.3) to enhance both labeling yield and specific activity. Uses of .sup.18F-TFB are also contemplated.

The present invention relates to the use of radiopharmaceuticals having a radioactive half-life of less than 21 minutes, such as oxygen-15 labeled water (H.sub.2.sup.15O) in blood flow imaging using PET (Positron emission tomography) scanning technology. The invention also relates to the use of a system for preparing and injecting boluses of such radiopharmaceuticals.

The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to .sup.99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives stabilized .sup.99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.

A radioactive thermogel suspension, including a thermogel and a plurality of radioactive yttrium phosphate particles suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03 um and 10 um in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

A radioactive thermogel suspension, including a thermogel and a plurality of radioactive yttrium phosphate particles suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03 um and 10 um in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

Embodiments of the invention provide methods of synthesizing .sup.18F-tetrafluoroborate (.sup.18F-TFB) via direct radiofluorination on boron trifluoride (BF.sub.3) to enhance both labeling yield and specific activity. Uses of .sup.18F-TFB include imaging of thyroid or breast cancer, and imaging of thyroid, breast, stomach, salivary glands or kidney.

A radioactive yttrium phosphate suspension, including a phosphate buffered saline solution and a plurality of radioactive yttrium phosphate particles suspended in the phosphate buffered saline solution. The plurality of radioactive yttrium phosphate particles are between 0.1 um to 2 um in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 40 mg/ml to 125 mg/ml.

A radioactive yttrium phosphate suspension, including a phosphate buffered saline solution and a plurality of radioactive yttrium phosphate particles suspended in the phosphate buffered saline solution. The plurality of radioactive yttrium phosphate particles are between 0.1 um to 2 um in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 40 mg/ml to 125 mg/ml.